Amphera announces publication of the positive results of the phase II trial in resected pancreatic cancer (REACTIVE) in the Journal of Clinical Oncology (ASCO), one of the world’s leading scientific journals.

The conclusion of the article: “This study reached its primary end point of a 2-year RFS rate of ≥60% following pancreatectomy after SOC treatment and adjuvant DC-based immunotherapy in patients with pancreatic cancer. These results warrant a future randomized trial.”